Promethera Biosciences Competitors and Similar CompaniesClear all

Promethera Biosciences's competitors and similar companies include Intercept Pharmaceuticals, Poxel, Gilead Sciences, Novartis, Allergan, Genfit and Pfizer.
Promethera Biosciences
Promethera Biosciences
Promethera Biosciences is a healthcare company developing cell therapy technologies for chronic liver diseases.
Intercept Pharmaceuticals
Intercept Pharmaceuticals
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases.
Poxel
Poxel
Poxelis a research integrated pharmaceutical company that develops products for metabolic diseases.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Allergan
Allergan
Allergan is a healthcare company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products.
Genfit
Genfit
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs.
Pfizer
Pfizer
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
Founding Date
Founding Date
2009
Founding Date
2002
Founding Date
2009
Founding Date
1987
Founding Date
1996
Founding Date
1948
Founding Date
1999
Founding Date
1849
Type
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Type
Public
Tags
Locations
Locations
Mont-Saint-Guibert, BE HQ
Charleroi, BE
Ganshoren, BE
Chuo City, JP
Chuo City, JP
Basel, CH
Durham, US
see more
Locations
New York, US HQ
Wien, AT
Mississauga, CA
Kongens Lyngby, DK
Paris, FR
München, DE
Dublin, IE
see more
Locations
Lyon, FR HQ
Chiyoda City, JP
Cambridge, US
Locations
Foster City, US HQ
Buenos Aires, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Basel, CH HQ
Tirana, AL
Buenos Aires, AR
Macquarie Park, AU
Kundl, AT
Unterlangkampfen, AT
Wien, AT
see more
Locations
Dublin, IE HQ
Buenos Aires, AR
Roseville, AU
Machelen, BE
Guarulhos, BR
Las Condes, CL
Bogotá, CO
see more
Locations
Loos, FR HQ
Cambridge, US
Locations
New York, US HQ
Buenos Aires, AR
Villa Adelina, AR
Footscray, AU
Mulgrave, AU
Sydney, AU
Wien, AT
see more
Employees
Employees
185% decrease
Employees
58321% increase
Employees
6
Employees
18,0006% increase
Employees
75,883
Employees
10,5471% decrease
Employees
180
Employees
81,0008% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
794.7 m
Valuation ($)
18.3 m
Valuation ($)
110.5 b
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
280.8 m
Valuation ($)
163.9 b

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$285.7m (FY, 2022)
Revenue (est.)
€6.6m (FY, 2024)
Revenue (est.)
$29.4b (FY, 2025)
Revenue (est.)
$56.7b (FY, 2025)
Revenue (est.)
N/A
Revenue (est.)
€65.4m (FY, 2025)
Revenue (est.)
$62.6b (FY, 2025)
Cost of goods
Cost of goods
N/A
Cost of goods
$984k (FY, 2022)
Cost of goods
€2.8m (FY, 2024)
Cost of goods
$6.2b (FY, 2025)
Cost of goods
$8.4b (FY, 2025)
Cost of goods
N/A
Cost of goods
€302k (FY, 2025)
Cost of goods
$16.1b (FY, 2025)
Gross profit
Gross profit
N/A
Gross profit
$284.7m (FY, 2022)
Gross profit
€3.8m (FY, 2024)
Gross profit
$23.2b (FY, 2025)
Gross profit
$49.8b (FY, 2025)
Gross profit
N/A
Gross profit
€70.8m (FY, 2025)
Gross profit
$46.5b (FY, 2025)
Net income
Net income
N/A
Net income
$221.8m (FY, 2022)
Net income
(€18.3m) (FY, 2024)
Net income
$8.5b (FY, 2025)
Net income
$14b (FY, 2025)
Net income
N/A
Net income
(€86m) (FY, 2025)
Net income
$7.8b (FY, 2025)

Operating

Countries
Countries
N/A
Countries
N/A
Countries
N/A
Countries
35 (FY, 2021)
Countries
N/A
Countries
100 (Q1, 2020)
Countries
N/A
Countries
200 (FY, 2024)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
9 (FY, 2021)
Phase III Trials Products
44 (FY, 2022)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
32 (FY, 2024)
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
4 (FY, 2021)
Phase III Trials Products (Oncology)
27 (FY, 2021)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Registration Phase Products
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
8 (FY, 2022)
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
5 (FY, 2024)

Funding

Total funding raised
Total funding raised
$ 146m
Total funding raised
$ 55m
Total funding raised
$ 33.8m
Total funding raised
N/A
Total funding raised
$ 6.5m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Intercept Pharmaceuticals
HQ
New York, US
Employees
583↑ 21% increase

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases.

View company
Poxel
HQ
Lyon, FR
Employees
6

Poxelis a research integrated pharmaceutical company that develops products for metabolic diseases.

View company
Gilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.

View company
Novartis
HQ
Basel, CH
Employees
75,883

Novartis is a company that researches, develops, manufactures, and markets healthcare products.

View company